Germany’s Emperra has raised a $3.1 million Series B round led by Robert Bosch Venture Capital GmbH (RBVC), a VC arm of the Bosch Group. The company’s existing investors include Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. Emperra’s CEO Dr. Krey and CTO Dr. Schildt also participated in the round. The company will use the money for further product development and to accelerate international growth, predominantly in the United States and Europe.

Emperra’s flagship product ESYSTA is a digital diabetes management solution consisting of smart hardware and software. It includes smart insulin pens, wireless blood glucose meters, and CE-certified software that work together seamlessly. The therapy data can be shared among all stakeholders (patient, physicians, nurses, caregivers) and displayed via multiple channels, including a web-based portal, smart TV, and apps.

“Involving high-quality investors such as Bosch demonstrates the potential in our unique approach to diabetes care,” Dr. Christian Krey, CEO of Emperra, said in a statement. “In particular, having Bosch as a strategic investor means we have access to its global expertise in software automation, connected communities, and sensor technologies.”

In Germany, ESYSTA has already received reimbursement status from German health insurers, which means ESYSTA hardware and software is now available on prescription for any patient with diabetes. Initial success in the German market confirms the effectiveness of this fully integrated diabetes care management.